CRISPR/SaCas9-based gene editing rescues photoreceptor degeneration throughout a rhodopsin-associated autosomal dominant retinitis pigmentosa mouse model
Restricted accessResearch articleFirst published online October, 2023
CRISPR/SaCas9-based gene editing rescues photoreceptor degeneration throughout a rhodopsin-associated autosomal dominant retinitis pigmentosa mouse model
Rhodopsin (Rho) gene mutation was considered the highest prevalent mutation in autosomal dominant retinitis pigmentosa (ADRP); however, effective therapeutics for ADRP have not been developed. The process of gene editing via the clustered regularly interspaced short palindromic repeat (CRISPR)/Cas9 system offers the potentiality to provide cures for dominantly inherited disorders. Herein, we generated a CRISPR/SaCas9-mediated gene reduction system to inactivate the Rho mutant, while replacing normal rhodopsin in a rhodopsin mutation mouse model. When Rho-P23H knock-in mice were administered a subretinal injection of the “reduction and replacement” system, the expression of mutant rhodopsin was reduced, and retinal function was improved. Therefore, we concluded that CRISPR/SaCas9-based “reduction and replacement” gene therapy could provide structural and functional benefits for Rho mutant ADRP, as well as new directions for future clinical research on the treatment of such gain-of-function genetic diseases.
IannacconeAManDWaseemNJenningsBJGanapathirajuMGallaherKReeseEBhattacharyaSSKlein-SeetharamanJ. Retinitis pigmentosa associated with rhodopsin mutations: correlation between phenotypic variability and molecular effects.Vision Res2006;46:4556–67
3.
DryjaTPMcGeeTLHahnLBCowleyGSOlssonJEReichelESandbergMABersonEL. Mutations within the rhodopsin gene in patients with autosomal dominant retinitis pigmentosa.N Engl J Med1990;323:1302–7
4.
MacLarenREGroppeMBarnardARCottriallCLTolmachovaTSeymourLClarkKRDuringMJCremersFPBlackGCLoteryAJDownesSMWebsterARSeabraMC. Retinal gene therapy in patients with choroideremia: initial findings from a phase 1/2 clinical trial.Lancet2014;383:1129–37
5.
BoyeSEBoyeSLLewinASHauswirthWW. A comprehensive review of retinal gene therapy.Mol Ther2013;21:509–19
6.
MussolinoCSangesDMarroccoEBonettiCDi VicinoUMarigoVAuricchioAMeroniGSuraceEM. Zinc-finger-based transcriptional repression of rhodopsin in a model of dominant retinitis pigmentosa.EMBO Mol Med2011;3:118–28
7.
JiangLZhangHDizhoorAMBoyeSEHauswirthWWFrederickJMBaehrW. Long-term RNA interference gene therapy in a dominant retinitis pigmentosa mouse model.Proc Natl Acad Sci U S A2011;108:18476–81
8.
LaVailMMYasumuraDMatthesMTDrenserKAFlanneryJGLewinASHauswirthWW. Ribozyme rescue of photoreceptor cells in P23H transgenic rats: long-term survival and late-stage therapy.Proc Natl Acad Sci USA2000;97:11488–93
9.
LewinASDrenserKAHauswirthWWNishikawaSYasumuraDFlanneryJGLaVailMM. Ribozyme rescue of photoreceptor cells in a transgenic rat model of autosomal dominant retinitis pigmentosa.Nat Med1998;4:967–71
10.
NiuYShenBCuiYChenYWangJWangLKangYZhaoXSiWLiWXiangAPZhouJGuoXBiYSiCHuBDongGWangHZhouZLiTTanTPuXWangFJiSZhouQHuangXJiWShaJ. Generation of gene-modified cynomolgus monkey via Cas9/RNA-mediated gene targeting in one-cell embryos.Cell2014;156:836–43
11.
DayTPByrneLCSchafferDVFlanneryJG. Advances in AAV vector development for gene therapy in the retina.Adv Exp Med Biol2014;801:687–93
12.
WangHYangHShivalilaCSDawlatyMMChengAWZhangFJaenischR. One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering.Cell2013;153:910–8
13.
MaliPYangLEsveltKMAachJGuellMDiCarloJENorvilleJEChurchGM. RNA-guided human genome engineering via Cas9.Science2013;339:823–6
14.
LiJFNorvilleJEAachJMcCormackMZhangDBushJChurchGMSheenJ. Multiplex and homologous recombination-mediated genome editing in Arabidopsis and Nicotiana benthamiana using guide RNA and Cas9.Nat Biotechnol2013;31:688–91
15.
HwangWYFuYReyonDMaederMLTsaiSQSanderJDPetersonRTYehJRJoungJK. Efficient genome editing in zebrafish using a CRISPR-Cas system.Nat Biotechnol2013;31:227–9
16.
RanFACongLYanWXScottDAGootenbergJSKrizAJZetscheBShalemOWuXMakarovaKSKooninEVSharpPAZhangF. In vivo genome editing using Staphylococcus aureus Cas9.Nature2015;520:186–91
17.
ZurisJAThompsonDBShuYGuilingerJPBessenJLHuJHMaederMLJoungJKChenZYLiuDR. Cationic lipid-mediated delivery of proteins enables efficient protein-based genome editing in vitro andin vivo. Nat Biotechnol2015;33:73–80
18.
SwiechLHeidenreichMBanerjeeAHabibNLiYTrombettaJSurMZhangF. In vivo interrogation of gene function in the mammalian brain using CRISPR-Cas9.Nat Biotechnol2015;33:102–6
19.
DalkaraDByrneLCLeeTHoffmannNVSchafferDVFlanneryJG. Enhanced gene delivery to the neonatal retina through systemic administration of tyrosine-mutated AAV9.Gene Ther2012;19:176–81
20.
FlanneryJGZolotukhinSVaqueroMILaVailMMMuzyczkaNHauswirthWW. Efficient photoreceptor-targeted gene expression in vivo by recombinant adeno-associated virus.Proc Natl Acad Sci USA1997;94:6916–21
21.
CanverMCHaeusslerMBauerDEOrkinSHSanjanaNEShalemOYuanGCZhangFConcordetJPPinelloL. Integrated design, execution, and analysis of arrayed and pooled CRISPR genome-editing experiments.Nat Protoc2018;13:946–86
22.
PinelloLCanverMCHobanMDOrkinSHKohnDBBauerDEYuanGC. Analyzing CRISPR genome-editing experiments with CRISPResso.Nat Biotechnol2016;34:695–7
23.
MichonJJLiZLShiouraNAndersonRJTsoMO. A comparative study of methods of photoreceptor morphometry.Invest Ophthalmol Vis Sci1991;32:280–4
24.
SakamiSMaedaTBeretaGOkanoKGolczakMSumarokaARomanAJCideciyanAVJacobsonSGPalczewskiK. Probing mechanisms of photoreceptor degeneration in a new mouse model of the common form of autosomal dominant retinitis pigmentosa due to P23H opsin mutations.J Biol Chem2011;286:10551–67
25.
TsaiYTWuWHLeeTTWuWPXuCLParkKSCuiXJustusSLinCSJaureguiRSuPYTsangSH. Clustered regularly interspaced short palindromic repeats-based genome surgery for the treatment of autosomal dominant retinitis pigmentosa.Ophthalmology2018;125:1421–30
26.
SakamiSKolesnikovAVKefalovVJPalczewskiK. P23H opsin knock-in mice reveal a novel step in retinal rod disc morphogenesis.Hum Mol Genet2014;23:1723–41
27.
LewinASRossmillerBMaoH. Gene augmentation for adRP mutations in RHO.Cold Spring Harb Perspect Med2014;4:a017400
28.
GorbatyukMJustilienVLiuJHauswirthWWLewinAS. Preservation of photoreceptor morphology and function in P23H rats using an allele independent ribozyme.Exp Eye Res2007;84:44–52
29.
KiangASPalfiAAderMKennaPFMillington-WardSClarkGKennanAO’reillyMTamLCAherneAMcNallyNHumphriesPFarrarGJ. Toward a gene therapy for dominant disease: validation of an RNA interference-based mutation-independent approach.Mol Ther2005;12:555–61
30.
CashmanSMBinkleyEAKumar-SinghR. Towards mutation-independent silencing of genes involved in retinal degeneration by RNA interference.Gene Ther2005;12:1223–8
31.
LamJKChowMYZhangYLeungSW. siRNA versus miRNA as therapeutics for gene silencing.Mol Ther Nucleic Acids2015;4:e252
32.
PecotCVCalinGAColemanRLLopez-BeresteinGSoodAK. RNA interference in the clinic: challenges and future directions.Nat Rev Cancer2011;11:59–67
33.
JacksonALLinsleyPS. Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application.Nat Rev Drug Discov2010;9:57–67
34.
LiPKleinstiverBPLeonMYPrewMSNavarro-GomezDGreenwaldSHPierceEAJoungJKLiuQ. Allele-specific CRISPR-Cas9 genome editing of the single-base P23H mutation for rhodopsin-associated dominant retinitis pigmentosa.CRISPR J2018;1:55–64
35.
BakondiBLvWLuBJonesMKTsaiYKimKJLevyRAkhtarAABreunigJJSvendsenCNWangS. In vivo CRISPR/Cas9 gene editing corrects retinal dystrophy in the S334ter-3 rat model of autosomal dominant retinitis pigmentosa.Mol Ther2016;24:556–63
36.
VagniPPerliniLEChenaisNALMarchettiTParriniMContestabileACanceddaLGhezziD. Gene editing preserves visual functions in a mouse model of retinal degeneration.Front Neurosci2019;13:945
37.
DalkaraDGoureauOMarazovaKSahelJA. Let there be light: gene and cell therapy for blindness.Hum Gene Ther2016;27:134–47
38.
Millington-WardSChaddertonNO’ReillyMPalfiAGoldmannTKiltyCHumphriesMWolfrumUBennettJHumphriesPKennaPFFarrarGJ. Suppression and replacement gene therapy for autosomal dominant disease in a murine model of dominant retinitis pigmentosa.Mol Ther2011;19:642–9
39.
OusteroutDGKabadiAMThakorePIMajorosWHReddyTEGersbachCA. Multiplex CRISPR/Cas9-based genome editing for correction of dystrophin mutations that cause Duchenne muscular dystrophy.Nat Commun2015;6:6244
40.
LatellaMCDi SalvoMTCocchiarellaFBenatiDGrisendiGComitatoAMarigoVRecchiaA. In vivo editing of the human mutant rhodopsin gene by electroporation of plasmid-based CRISPR/Cas9 in the mouse retina.Mol Ther Nucleic Acids2016;5:e389
41.
NelsonCEHakimCHOusteroutDGThakorePIMorebEACastellanos RiveraRMMadhavanSPanXRanFAYanWXAsokanAZhangFDuanDGersbachCA. In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy.Science2016;351:403–7
42.
BottaSMarroccoEde PriscoNCurionFRendaMSofiaMLupoMCarissimoABacciMLGesualdoCRossiSSimonelliFSuraceEM. Rhodopsin targeted transcriptional silencing by DNA-binding.eLife2016;5:e12242
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
